(Q45086821)

9 December 2017

title

Treatment of chronic hepatitis due to hepatitis B virus (English)

1 reference

9 December 2017

1 reference

1 reference

S Sherlock

1

1 reference

9 December 2017

H C Thomas

series ordinal

2

1 reference

9 December 2017

language of work or name

English

0 references

publication date

1 December 1985

1 reference

9 December 2017

1 reference

9 December 2017

volume

2

1 reference

9 December 2017

issue

8468

1 reference

9 December 2017

page(s)

1343-1346

1 reference

The detection of HBV-DNA in serum by molecular hybridisation: a more sensitive method for the detection of complete HBV particles

9 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2992636-4

7 January 2021

Hepatitis B virus infection: the impact of molecular biology.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2992636-4

7 January 2021

Natural history of liver disease in chronic hepatitis B surface antigen carriers. Survey of 100 patients from Great Britain

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2992636-4

7 January 2021

Seroconversion from Hepatitis B e Antigen to Antibody in Chronic Type B Hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2992636-4

7 January 2021

Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2992636-4

7 January 2021

State of hepatitis B virus DNA in hepatocytes of patients with hepatitis B surface antigen-positive and -negative liver diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2992636-4

7 January 2021

Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2992636-4

7 January 2021

Susceptibility of chronic symptomless HBsAg carriers to ethanol-induced hepatic damage

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2992636-4

7 January 2021

Successful treatment of HBs and HBeAg positive chronic liver disease: prolonged inhibition of viral replication by highly soluble adenine arabinoside 5'-monophosphate (ARA-AMP).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2992636-4

7 January 2021

Randomised controlled trial of adenine arabinoside 5'-monophosphate (ARA-AMP) in chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2992636-4

7 January 2021

Antiviral therapy in hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2992636-4

7 January 2021

Neurotoxicity associated with adenine arabinoside monophosphate in the treatment of chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2992636-4

7 January 2021

Interferon and hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2992636-4

7 January 2021

Hepatitis B virus and HLA antigen display in the liver during chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2992636-4

7 January 2021

A randomized study of the effects of adenine arabinoside 5'-monophosphate (short or long courses) and lymphoblastoid interferon on hepatitis B virus replication.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2992636-4

7 January 2021

Thrice weekly lymphoblastoid interferon is effective in inhibiting hepatitis B virus replication

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2992636-4

7 January 2021

Recombinant leukocyte a interferon treatment in patients with chronic hepatitis B virus infection. Pharmacokinetics, tolerance, and biologic effects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2992636-4

7 January 2021

Acyclovir inhibits hepatitis B virus replication in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2992636-4

7 January 2021

Acyclovir enhances the antiviral effect of interferon in chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2992636-4

7 January 2021

Effects of prednisolone/azathioprine in chronic hepatitis B viral infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2992636-4

7 January 2021

Comparative efficacy of adenine arabinoside 5' monophosphate and prednisone withdrawal followed by adenine arabinoside 5' monophosphate in the treatment of chronic active hepatitis type B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2992636-4

7 January 2021

Combination of short-term prednisolone and adenine arabinoside in the treatment of chronic hepatitis B. A controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2992636-4

7 January 2021

Liver disease activity and hepatitis B virus replication in chronic delta antigen-positive hepatitis B virus carriers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2992636-4

7 January 2021

Prednisolone in HBsAg-positive chronic active hepatitis: histologic evaluation in a controlled prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2992636-4

7 January 2021

Effect of immunosuppressive therapy on HBsAg-positive chronic active hepatitis in relation to presence or absence of HBeAg and anti-HBe

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2992636-4

7 January 2021

The detrimental effects of adrenocorticosteroid therapy in HBsAg-positive chronic active hepatitis: fact or artifact?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2992636-4

7 January 2021

INFLUENCE OF DELTA INFECTION ON SEVERITY OF HEPATITIS B

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2992636-4

7 January 2021

10.1016/S0140-6736(85)92636-4

Identifiers

DOI

1 reference

9 December 2017

1 reference